ChangchunDengMD

Oncology • New York, NY

Assistant Professor

Join to view full profile

Dr. Deng is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Deng's full profile

Already have an account?

Office
177 Fort Washington Ave
# 6GN-435
New York, NY 10032
Phone+1 212-305-0983

Fax+1 212-305-3035

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2008 - 2010
University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2008
Lincoln Medical and Mental Health CenterResidency, Internal Medicine, 2004 - 2007
Suzhou Medical CollegeClass of 1990

Certifications & Licensure

CA State Medical License 2012 - Present
NY State Medical License 2008 - 2026
OH State Medical License 2022 - 2026
PA State Medical License 2022 - 2024
TX State Medical License 2008 - 2012
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Publications & Presentations

PubMed

91 citations
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma
Jennifer E Amengual, Renee Lichtenstein, Jennifer K. Lue, Ahmed Sawas, Changchun Deng
Blood. 2018-01-25
59 citations
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously expos...
Ahmed Sawas, Charles M. Farber, Marshall T. Schreeder, Mazen Khalil, Daruka Mahadevan
British Journal of Haematology. 2017-04-01
92 citations
Multiple Endonucleases Function to Repair Covalent Topoisomerase I Complexes in Saccharomyces cerevisiae
Changchun Deng, James A. Brown, Dongqing You, J. Martin Brown
Genetics. 2005-06-01

Journal Articles

Brentuximab Vedotin and Bendamustine Produce High Complete Response Rates in Patients with Chemotherapy Refractory Hodgkin Lymphoma
Changchun Deng, Markus Y. Mapara, Ahmed Sawas, Matko Kalac, British Journal of Haematology

Abstracts/Posters

Targeting eIF4A Using MZ-735 Potently Induces Cell Death in Lymphoma Cells and Rapidly Represses mRNA Translation at the Global Level and in C-MYC and Other Oncogenes
Changchun Deng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype
Changchun Deng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Casein Kinase 1 Delta Is a Novel Regulator of mRNA Translation and Druggable Target in Aggressive Lymphomas
Changchun Deng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

CUIMC Celebrates 2019-20, Issue 4February 19th, 2020